QSAR of 2-(4-methylsulphonylphenyl)pyrimidine derivatives as cyclooxygenase-2 inhibitors: Simple structural fragments as potential modulators of activity

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 27, Issue 2, 2012, Pages 249-260

  Sharma, B K ^a   Singh, P ^a   Pilania, P ^a   Shekhawat, M ^a   Prabhakar, Y S ^b  

^a SK Government College   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

2 (4 Methylsulphonylphenyl)pyrimidines; Combinatorial protocol in multiple linear regression (CP MLR); COX 2 inhibitory activity; Dragon descriptors; Partial least square (PLS) analysis

Indexed keywords

2(4 METHYLSULPHONYLPHENYL) PYRIMIDINE DERIVATIVE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; COMBINATORIAL CHEMISTRY; ENZYME INHIBITION; HUMAN; IC 50; MODEL; MULTIPLE LINEAR REGRESSION ANALYSIS; PARTIAL LEAST SQUARES REGRESSION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

COMBINATORIAL CHEMISTRY TECHNIQUES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; LEAST-SQUARES ANALYSIS; MODELS, CHEMICAL; MODELS, THEORETICAL; MOLECULAR STRUCTURE; PYRIMIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84858139210     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2011.587414     Document Type: Article

References (53)

1. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P. Te induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265:16737-16740.
2. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-2696. (Pubitemid 21916484)
3. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992;89:7384-7388.
4. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-12872.
5. Vane J. Towards a better aspirin. Nature 1994;367:215-216. (Pubitemid 24051134)
6. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinfammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-3232. (Pubitemid 24130209)
7. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120. (Pubitemid 28231490)
8. Garavito RM, DeWitt DL. Te cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim Biophys Acta 1999;1441:278-287. (Pubitemid 29537747)
9. Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W et al. Te discovery of rofecoxib [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3- phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 1999;9:1773-1778.
10. Merck & Co. Press Release; 30 September 2004. http://www.merck. com
11. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-959. (Pubitemid 33010342)
12. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-infammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363:1751-1756. (Pubitemid 38698377)
13. Scheen AJ. [Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-infammatory drugs?]. Rev Med Liege 2004;59:565-569. (Pubitemid 39573114)
14. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al.; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102. (Pubitemid 40365350)
15. Solomon SD, McMurray JJ, Pfefer MA, Wittes J, Fowler R, Finn P et al.; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080. (Pubitemid 40365348)
16. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-1711.
17. Lagakos SW. Time-to-event analyses for long-term treatments-the APPROVe trial. N Engl J Med 2006;355:113-117. (Pubitemid 44050391)
18. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identifcation of 4-[5-(4-methylphenyl)-3- (trifuoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 1997;40:1347-1365. (Pubitemid 27198082)
19. Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 2000;43:775-777. (Pubitemid 30152286)
20. Ormrod D, Wellington K, Wagstaf AJ. Valdecoxib. Drugs 2002;62:2059-2071; discussion 2072. (Pubitemid 35204038)
21. Friesen RW, Brideau C, Chan CC, Charleson S, Deschênes D, Dubé D et al. 2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 1998;8:2777-2782. (Pubitemid 28496986)
22. Riendeau D, Percival MD, Brideau C, Charleson S, Dubé D, Ethier D et al. Etoricoxib (MK-0663): preclinical profle and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ter 2001;296:558-566. (Pubitemid 32112486)
23. Davies IW, Marcoux JF, Corley EG, Journet M, Cai DW, Palucki M et al. A practical synthesis of a COX-2-specifc inhibitor. J Org Chem 2000;65:8415-8420.
24. Paul AD, Shah E, Richard MM, Peter J. Lessons from the withdrawal of rofecoxib: patients would be safer if drug companies disclosed adverse events before licensing. Br Med J 2004;329:867-868.
25. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879-890.
26. Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci 2004;7:332-336. (Pubitemid 41528882)
27. Chung S, Lim ML, Shin SS. Profles of COX-2 inhibitors: present and future. Expert Opin Ter Patents 2005;15:9-32. (Pubitemid 40220352)
28. Dogné JM, Supuran CT, Pratico D. Adverse cardiovascular efects of the coxibs. J Med Chem 2005;48:2251-2257.
29. Dogné JM, Hanson J, Supuran C, Pratico D. Coxibs and cardiovascular side-efects: from light to shadow. Curr Pharm Des 2006;12:971-975.
30. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116:4-15. (Pubitemid 43121782)
31. Sohn HY, Krötz F. Cyclooxygenase inhibition and atherothrombosis. Curr Drug Targets 2006;7:1275-1284. (Pubitemid 44509690)
32. Maillard M, Burnier M. Comparative cardiovascular safety of traditional nonsteroidal anti-infammatory drugs. Expert Opin Drug Saf 2006;5:83-94. (Pubitemid 43056441)
33. Hermann M, Ruschitzka F. Coxibs, non-steroidal anti-infammatory drugs and cardiovascular risk. Intern Med J 2006;36:308-319.
34. Orjales A, Mosquera R, López B, Olivera R, Labeaga L, Núñez MT. Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specifc COX-2 inhibitors. Bioorg Med Chem 2008;16:2183-2199. (Pubitemid 351380955)
35. Shah UA, Deokar HS, Kadam SS, Kulkarni VM. Pharmacophore generation and atom-based 3D-QSAR of novel 2-(4-methylsulfonylphenyl)pyrimidines as COX-2 inhibitors. Mol Divers 2010;14:559-568.
36. Khare A, Trivedi S, Rajak H, Pawar RS, Patil UK, Singour PK. Hansch analysis of novel pyrimidine derivatives as highly potent and specifc COX-2 inhibitors. Med Chem Res. DOI: 10.1007/s00044-011-9566-8.
37. Todeschini R, Consonni V. Dragon Software (version 1.11-2001). Milano, Italy
38. Chemdraw Ultra 6.0 and Chem3D Ultra, Cambridge Soft Corporation, Cambridge, USA.
39. Prabhakar YS. A combinatorial approach to the variable selection in multiple linear regression: analysis of Selwood et al. Data Set-a case study. QSAR Comb Sci 2003;22:583-595. (Pubitemid 37010625)
40. Wold S. Cross-validatory estimation of the number of components in factor and principal components models. Technometrics 1978;20:397-405.
41. Kettaneh N, Berglund A, Wold S. PCA and PLS with very large data sets. Comput Stat Data Anal 2005;48:69-85.
42. Stahle L, Wold S. Multivariate data analysis and experimental design, In: Ellis GP, West WB, eds. Biomedical Research, Progress in Medicinal Chemistry. Elsevier Science Publishers, BV,vol. 25, 1998, pp. 291-338.
43. So SS, Karplus M. Tree-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. Method and validations. J Med Chem 1997;40:4347-4359. (Pubitemid 28042314)
44. Prabhakar YS, Solomon VR, Rawal RK, Gupta MK, Katti SB. CP-MLR/PLS directed structure-activity modeling of the HIV-1 RT inhibitory activity of 2,3-diaryl-1,3-thiazolidin-4-ones. QSAR Comb Sci 2004;23:234-244. (Pubitemid 39490415)
45. Gramatica P. Principles of QSAR models validation: internal and external. QSAR Comb Sci 2007;26:694-701. (Pubitemid 46932857)
46. Golbraikh A, Tropsha A. Beware of q2! J Mol Graph Model 2002;20:269-276.
47. Tropsha A, Golbraikh A. UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA (personal communication), 2011.
48. Sachs L. Applied Statistics. A Handbook of Techniques. Springer-Verlag, Berlin, 1982.
49. Roy PP, Roy K. On some aspects of variable selection for partial least squares regression models. QSAR Comb Sci 2008;27:302-313.
50. Pratim Roy P, Paul S, Mitra I, Roy K. On two novel parameters for validation of predictive QSAR models. Molecules 2009;14:1660-1701.
51. Mitra I, Saha A, Roy K. Exploring quantitative structure-activity relationship studies of antioxidant phenolic compounds obtained from traditional Chinese medicinal plants. Mol Simulat 2010;36:1067-1079.
52. Hawkins DM, Basak SC, Mills D. Assessing model ft by cross-validation. j Chem Inf Comput Sci 2003;43:579-586.
53. Gupta MK, Prabhakar YS. Topological descriptors in modeling the antimalarial activity of 4-(3′,5′-disubstituted anilino)quinolines. J Chem Inf Model 2006;46:93-102. (Pubitemid 43282103)